|
Characteristic
|
ERGIC3−
|
ERGIC3+
|
P-value
|
|---|
|
Gender
| | |
0.279
|
|
Male
|
3/17 (18%)#
|
14/17 (82%)
| |
|
Female
|
1/18 (6%)
|
17/18 (94%)
| |
|
Age, y
| | |
/
|
|
Median
|
55.9
|
53.5
| |
|
Range
|
36-76
|
38-71
| |
|
Smoking
| | |
0.323
|
|
No
|
1/17 (6%)
|
16/17 (94%)
| |
|
Yes
|
3/18 (17%)
|
15/18 (83%)
| |
|
Histological type
| | |
0.014*
|
|
AC
|
0
|
22/22 (100%)
| |
|
SCC
|
4/13 (31%)
|
9/13 (69%)
| |
|
TNM stage
| | |
0.419
|
|
I + II
|
3/20 (15%)
|
17/20 (85%)
| |
|
III + IV
|
1/15 (7%)
|
14/15 (93%)
| |
|
Differentiation
| | |
0.006*
|
|
Poor
|
4/11 (36%)
|
7/11 (64%)
| |
|
Well or Moderate
|
0
|
24/24 (100%)
| |
- Statistical significance was determined by the Fisher’s exact test of chi-square test (two-tailed); #: Number of cases applicable/total number of cases examined (with percent in parenthesis); *: Statistically significant, P < 0.05.
- Abbreviations: SCC: squamous cell carcinoma; AC: adenocarcinoma; y: year.
